Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

South Korea · Delayed Price · Currency is KRW

8,070.00

-200.00 (-2.42%)

Sep 11, 2026, 3:30 PM KST

Market Cap	144.65B -38.2%
Revenue (ttm)	277.96B +0.6%
Net Income	16.84B +69.0%
EPS	968.50 +74.1%
Shares Out	17.92M
PE Ratio	8.33
Forward PE	n/a
Dividend	155.00 (1.83%)
Ex-Dividend Date	Dec 29, 2025

Volume	21,482
Open	8,120.00
Previous Close	8,270.00
Day's Range	8,030.00 - 8,180.00
52-Week Range	7,290.00 - 16,240.00
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About KRX:007570

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and be... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1946

Employees 666

Stock Exchange Korea Stock Exchange

Ticker Symbol 007570

Full Company Profile

Financial Performance

In 2025, KRX:007570's revenue was 272.42 billion, an increase of 1.39% compared to the previous year's 268.68 billion. Earnings were 6.73 billion, a decrease of -25.52%.

Financial Statements